T波电交替对心力衰竭患者的应用价值

摘要
图/表
参考文献
相关文章 (15)

［1］ Linde C， Daubert C. Cardiac resynchronization therapy in patients with New York Heart Association class I and II   heart failure: an approach to 2010［J］. Circulation，2010， 122（10）:1037-1043.
［2］ Kamath GS， Mittal S. The role of antiarrhythmic drug therapy for the prevention of sudden cardiac death［J］. Prog Cardiovasc Dis，2008，50（6）:439-448.
［3］ La Rovere MT， Bigger Jr JT， Marcus FI， et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI （Autonomic Tone and Reflexes After Myocardial Infarc- tion） Investigators［J］. Lancet，1998，351（9101）:478- 484.
［4］ Antzelevitch C. Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes［J］. Am J Physiol Heart Circ Physiol，2007，293（4）: H2024-H2038.
［5］ Harada M， Shimizu A， Murata M， et al. Relation between microvolt-level T-wave alternans and cardiac sympathetic nervous system abnormality using iodine-123 metaiodo-benzylguanidine imaging in patients with idiopathic dilated cardiomyopathy［J］. Am J Cardiol，2003，92（8）:998- 1001.
［6］ Kovach JA，Nearing BD，Verrier RL. Angerlike behavioral state potentiates myocardial ischemia-induced T-wave alternans in canines［J］. J Am Coll Cardiol，2001，37（6）:1719 -1725.
［7］ Armoundas AA， Tomaselli GF， Esperer HD. Pathophysiological basis and clinical application of T-wave alternans［J］. J Am Coll Cardiol，2002，40（2）:207-217.
［8］ Wilson LD， Jeyaraj D， Wan X， et al. Heart failure enhances susceptibility to arrhythmogenic cardiac alternans［J］. Heart Rhythm，2009，6（2）:251-259.
［9］ Narayan SM， Bayer JD， Lalani G， et al. Action potential dynamics explain arrhythmic vulnerability in human heart failure: a clinical and modeling study implicating abnormal   calcium handling［J］. J Am Coll Cardiol，2008，52（22）: 1782-1792.
［10］ Kleber AG， Janse MJ， Van Capelle F， et al. Mechanism   and time course of ST and TQ segment changes during acute regional myocardial ischemia in the pig heart deter- mined by extracellular and intracellular recordings［J］.   Circ Res，1978，42（5）:603-613.
［11］ Merchant FM， Armoundas AA. Role of substrate and triggers in the genesis of cardiac alternans，from the myocyte to the whole heart［J］. Circulation，2012，125（3）:539- 549.
［12］ Steenbergen C， Murphy E， Watts JA， et al . Correlation between cytosolic free calcium，contracture，ATP， and irreversible ischemic injury in perfused rat heart［J］. Circ   Res，1990，66（1）:135-146.
［13］ Pastore JM， Rosenbaum DS. Role of structural barriers in the mechanism of alternans-induced reentry［J］. Circ   Res，2000，87（12）:1157-1163.
［14］ Klingenheben T， Ptaszynski P， Hohnloser SH. Quantitative assessment of microvolt T-wave alternans in patients with congestive heart failure［J］. J Cardiovasc Electro- physiol，2005，16（6）:620-624.
［15］ Minkkinen M， Khnen M， Viik J， et al. Enhanced pre- dictive power of quantitative TWA during routine exercise   testing in the finnish cardiovascular study［J］. J Cardio- vasc Electrophysiol，2009，20（4）:408-415.
［16］ Leino J， Verrier RL， Minkkinen M， et al. Importance of   regional specificity of T-wave alternans in assessing risk   for cardiovascular mortality and sudden cardiac death dur- ing routine exercise testing［J］. Heart Rhythm，2011，8 （3）:385-390.
［17］ Bloomfield DM， Bigger JT， Steinman RC， et al. Micro- volt T-wave alternans and the risk of death or sustained   ventricular arrhythmias in patients with left ventricular   dysfunction［J］. J Am Coll Cardiol，2006，47（2）:456- 463.
［18］ Verrier RL， Klingenheben T， Malik M， et al. Microvolt   T-wave alternans: physiological basis， methods of meas- urement， and clinical utility—consensus guideline by international society for holter and noninvasive electrocardio- logy［J］. J Ame Coll Cardiol，2011，58（13）:1309- 1324.
［19］ Verrier RL， Nieminen T. T-wave alternans as a therapeutic marker for antiarrhythmic agents［J］. J Cardiovasc   Pharmacol，2010，55（6）:544-554.
［20］ Klingenheben T， Gronefeld G， Li YG， et al. Effect of metoprolol and d，l-sotalol on microvolt-level T-wave alternans: Results of a prospective，double-blind，randomized   study［J］. J Am Coll Cardiol， 2001，38（7）:2013- 2019.
［21］ Rashba EJ， Cooklin M， MacMurdy K， et al. Effects of selective autonomic blockade on T-wave alternans in humans［J］. Circulation，2002，105（7）:837-842.
［22］ Olsson G， Wikstrand J， Warnold I， et al. Metoprolol-in-   duced reduction in postinfarction mortality: pooled results   from five double-blind randomized trials［J］. Eur Heart J， 1992，13（1）:28-32.
［23］ Shusterman V， McTiernan CF， Goldberg A， et al. Adren- ergic stimulation promotes T-wave alternans and arrhyth- mia inducibility in a TNF-α genetic mouse model of con- gestive heart failure［J］. Am J Physiol Heart Circ Physi- ol，2010，298（2）:H440-H450.
［24］ Ellenbogen KA， Levine JH， Berger RD， et al. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardio- myopathy［J］.Circulation，2006，113（6）:776-782.
［25］ Mishkin JD， Saxonhouse SJ， Woo GW， et al. Appropriate evaluation and treatment of heart failure patients after implantable cardioverter-defibrillator discharge: time to go eyond the initial shock［J］. J Am Coll Cardiol，2009，54 （22）:1993-2000.
［26］ Bloomfield DM， Steinman RC， Namerow PB， et al. Mi- crovolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy［J］. Circulation，2004，110 （14）:1885-1889.
［27］ Merchant FM， Ikeda T， Pedretti RF， et al. Clinical utility of microvolt T-wave alternans testing in identifying patients at high or low risk of sudden cardiac death［J］.   Heart Rhythm，2012.［Epub ahead of print］
［28］ Hohnloser SH， Ikeda T， Cohen RJ. Evidence regarding   clinical use of microvolt T-wave alternans［J］. Heart   Rhythm，2009，6（3）:S36-S44.
［29］Zizek D， Cvijic M， Tasi c J， et al. Effect of cardiac resynchronization therapy on beat-to-beat T-wave amplitude variability［J］. Europace，2012.［Epub ahead of print］
［30］ Markowitz SM， Lewen JM， Wiggenhorn CJ， et al. Relationship of reverse anatomical remodeling and ventricular arrhythmias after cardiac resynchronization［J］. J Cardio- vas Electrophysiol，2009，20（3）:293-298.
［31］ Lellouche N， De Diego C， Boyle NG， et al. Relationship between mechanical and electrical remodelling in patients with cardiac resynchronization implanted defibrillators ［J］. Europace，2011，13（8）:1180-1187.
［32］ Cleland JG， Daubert JC， Erdmann E， et al. Longer-term effects of cardiac resynchronization therapy on mortality in   heart failure［the CArdiac REsynchronization-Heart Failure（CARE-HF） trial extension phase］［J］. Eur Heart   J，2006，27（16）:1928-1932.